Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07250802 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT07250802 is a Phase 3 study of Plaque Psoriasis that is actively recruiting participants, run by Takeda. The registered enrollment target is 110 participants, below the 413-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT07250802, a Phase 3 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children. At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate once enough information has been collected from other studies with zasocitinib. Participants in Part A will initially be assigned to receive either zasocitinib or placebo for the first 16 weeks of treatment, then all participants will receive zasocitinib through the end of the study. All participants in Part B will be assigned to receive treatment with zasocitinib throughout the study. Participants will be in the study for up to 4 years and 2 months (217 weeks), including up to 35 days for the screening period, 208 weeks of treatment (Part A and Part B) and a 4-week safety follow-up period. During the study, participants will visit their study site multiple times.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zasocitinib
Study Locations (20)
Ohio
- Apex Clinical Research Center, LLC - Canton
- Wright State Physicians - Fairborn
- Apex Clinical Research Center, LLC - Mayfield Heights
California
- Exalt Clinical Research - Chula Vista
- First OC Dermatology Research Inc. - Fountain Valley
Texas
- UT Physicians Dermatology - Bellaire Station - Bellaire
- Texas Dermatology and Laser Specialists-San Antonio - San Antonio
Other
- Peking University Third Hospital - Beijing
- Huashan Hospital Fudan University - Shanghai
Florida
- Direct Helpers Medical Center - Hialeah
Illinois
- Arlington Dermatology - Rolling Meadows
South Carolina
- Medical University of South Carolina - Charleston
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2033-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07250802
The ClinicalTrials.gov registry entry for NCT07250802 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 413-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (73% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07250802 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Ohio, California, Texas.
Frequently Asked Questions
What is clinical trial NCT07250802 about?
NCT07250802 is a clinical study titled "A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis". The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B wi...
What is the current status of trial NCT07250802?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2025-12-04. Estimated completion is 2033-01-24.
What conditions does trial NCT07250802 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT07250802?
The interventions under investigation include: Placebo (DRUG), Zasocitinib (DRUG).
Who is sponsoring clinical trial NCT07250802?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07250802 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.